Yondelis 1 Mg Powder

About Yondelis 1 Mg Powder

Yondelis 1 mg Yondelis Generic Content-Trabectedin also known as ecteinascidin, Manufactured By : Janssen Pharmaceutica, Belgium Yondelisis an anti-tumor drug. Yondelis is approved for the treatment of advanced soft tissue sarcoma.

Taken into use in the treatment or cure of adult patients with higher soft tissue sarcoma, following failure of ifosfamide and anthracyclines, or who are unsuitable to be given these agents, Yondelis (also recognized as Ecteinascidin 743 or ET-743 or Trabectedin) is a famous anti-tumor drug. Efficiency data depends largely on leiomyosarcoma and liposarcoma patients. This in blend with pegylated liposomal doxorubicin (PLD) is used for the treatment of people suffering with relapsed platinum-sensitive ovarian cancer. Johnson and Johnson, and Zeltia manufacture the medication under the brand Yondelis.

• Brand Name: Yondelis 1mg
• Form: Injection powder
• Contents: Trabectedin
• Strength: 0.25mg & 1mg
• Manufactured By: J & J
• Packing: Injection
• Manufacturer: Johnson & Johnson Belgium.

The U.S. Food and Drug Administration (FDA) and the European Commission have approved orphan drug class to trabectedin for ovarian cancer and soft tissue sarcomas.

Side-Effects :

Medications and their probable side effects can influence certain people in dissimilar ways. Below are listed some of the common side effects that are identified to be associated with the usage of this medicine. Just as a side effect is confirmed, here does not mean that all individuals using this medicine will feel or go through that or any side effect.

• Disorder of the gut, like constipation, nausea and vomiting, indigestion, diarrhoea, abdominal pain.
• Decline in the counting of white blood cells (neutropenia), red blood cells (anemia) or platelets (thrombocytopenia) in the blood.
• Weakness, Fatigue, or loss of strength (asthenia).
• Weight loss and loss of appetite.
• Headache
• Injection site reaction.
• Higher levels of liver enzymes.
• Troubles with the nerves, for instance causing transformation in sensation like needles and pins (paraesthesia) or numbness.
• Dizziness.
• Shortness of breath or dyspnoea.
• Pain in joints or muscle (myalgia or arthralgia).
• Fever.
• Hair loss (alopecia).
• Swollen ankles or peripheral oedema.
• Difficulty sleeping or insomnia.
• Low blood pressure or hypotension.
• Bacterial, fungal infections, or serious viral sometimes
• Inflammation of the mouth like or stomatitis.
• Breakdown of Muscle (rhabdomyolysis).

Import License No. FF-116-15404 for 1 vial, Inclusive of all taxes
Beerse, Belgium
Imported & Marketed in India by
30, Forjett Street, Mumbai 400036

Strict Intravenous Administration

Yondelis is formulated exclusively for intravenous infusion after proper dilution. Reconstitution is performed with sterile water for injection, ensuring a clear, colorless to slightly yellow solution suitable for safe administration by trained medical personnel. This stringent preparation process helps maintain its efficacy and reduce risk during treatment.


Handled with Cytotoxic Precautions

As a potent cytotoxic anticancer agent, Yondelis requires careful handling in line with cytotoxic drug guidelines. healthcare staff should use protective equipment when preparing and administering the product to ensure safety. Proper disposal methods for unused material and equipment are also essential to safeguard the environment and personnel.


Approved for Targeted Indications

Yondelis has received regulatory approval from the EMA and US FDA for the management of specific cancers, including soft tissue sarcoma and ovarian cancer. High purity and sterility make it a reliable option for eligible patients. Detailed batch and expiry data are available with every pack, ensuring traceability and peace of mind.